Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (4439)	1/9/1998 1:44:00 PM
From: go_bucks	Read Replies (1) \| Respond to of 23519

haven't seen this posted yet... excerpt: Prostaglandin E-1 is a naturally occurring vasodilator originally approved by the U.S. FDA for intravenous infusion in neonates. PGE-1 was first approved by the FDA in 1995, for Upjohn's Caverject(r), a treatment for male erectile dysfunction administered by needle injection and approved in November 1996, for Vivus Inc [Nasdaq:VVUS - news].'s MUSE(r) delivery system. The company believes that its product represents a tremendous treatment advantage over other delivery systems currently being utilized in the industry. i know nothing about drugs but sounds positive to me :) charlie for the full story, biz.yahoo.com